Besunyen Holdings Company Limited provided earnings guidance for the year ended December 31, 2018. The board of directors of the company estimated that the Group may record a net loss attributable to the shareholders of the Company of approximately RMB 80 million to RMB 100 million for the year ending 31 December 2018. This is mainly attributable to: (i) the Group's adjustment of its management policy for offline distributors/sub-distributors and the incentive policy for its sales staff this year as disclosed in the announcement of the Company dated 6 May 2018, which helped lessen disruptive market behaviours, strengthened channel management and enhanced the good market operation order for end-sales at pharmacies but led to a decrease in the revenue of the Group from offline products this year; and (ii) the estimated increase of approximately 65% of the research and development investment by the Group as compared to the corresponding period of last year, which is mainly attributed to the research, development and reserve of new products by Zhongshan Wanhan Pharmacy Co. Ltd. and Zhongshan Wanyuan New Medicine Research and Development Co. Ltd., the indirect wholly-owned subsidiaries of the company.